
Lectures

Questions and answers

Quiz

Certificate of completion
Test your knowledge!

TRUE OR FALSE?
Study design plays an instrumental role when evaluating the clinical utility of lung cancer screening and the added value of new tools, such as biomarkers and artificial intelligence.
Enroll in this course to find out.
WATCH THE VIDEO EXCERPT!
Date of the recording: 6 December 2022
Webinar organized with the support of and in collaboration with the European Society for Medical Oncology (ESMO).
INTRODUCTION BY

Dr Rosa Giuliani
Consultant in Medical Oncology, Clatterbridge Cancer Centre, United KingdomDirector of Public Policy, European Society for Medical Oncology (ESMO)
SPEAKERS
LUNG CANCER SCREENING: WHERE DO WE STAND?

Professor Joachim Aerts
Head, Department of Pulmonary MedicineErasmus University Medical Center, Netherlands
There is a lot of debate about the efficacy of lung cancer screening. This presentation will discuss the latest state of affairs of the published data on lung cancer screening
THE FUTURE OF LUNG CANCER SCREENING: RISK PREDICTION, BIOMARKERS, AND ARTIFICIAL INTELLIGENCE
Dr Hilary Robbins
Scientist, Genomic Epidemiology BranchInternational Agency for Research on Cancer, Lyon, France

Lung cancer screening programmes can be made more effective and efficient by using information about individual risk to tailor aspects of eligibility, screening frequency, and nodule follow-up. This presentation will discuss research developments in predicting lung cancer occurrence using statistical models, blood-based biomarkers, and artificial intelligence with low-dose computed tomography (CT) images.
CONTENT
To access the content: 1) login/register to the platform; 2) click on the “Enrol” button. The page will refresh and you will be able to click on the cards below.
CERTIFICATE
Mark all learning sequences as “completed” and obtain a minimum score of 80% on the quiz to be able to download your Certificate of Completion.